
Commentary|Videos|May 29, 2024
Homing in on the TOPAZ-1 Trial in Biliary Tract Cancer
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple Myeloma
4
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
5

